Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedSep 23, 2015Sodium Tetradecyl Sulfate 5% InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1635-2015Class IITerminatedSep 23, 2015Sodium Ascorbate 500 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1634-2015Class IITerminatedSep 23, 2015Sermorelin 300 mcg/ml + GHRP-2 300 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1633-2015Class IITerminatedSep 23, 2015Sermorelin 1000mcg/GHRP6 1000/GHRP2 1000 ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1632-2015Class IITerminatedSep 23, 2015Sermorelin/GHRP6 1000/1000 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1631-2015Class IITerminatedSep 23, 2015Sermorelin/GHRP2 1000/1000 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1630-2015Class IITerminatedSep 23, 2015Sermorelin 1000 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1629-2015Class IITerminatedSep 23, 2015Selenium 200 mcg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1628-2015Class IITerminatedSep 23, 2015Pyridoxine Hydrochloride 100 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1627-2015Class IITerminatedSep 23, 2015Progesterone 100 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1626-2015Class IITerminatedSep 23, 2015Polidocanol 5% InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1625-2015Class IITerminatedSep 23, 2015Polidocanol 1% InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1624-2015Class IITerminatedSep 23, 2015Phosphatidylcholine 0.1% Sodium Deoxycholate 0.089% InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1623-2015Class IITerminatedSep 23, 2015PGE 80 (Alprostadil) 80 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1622-2015Class IITerminatedSep 23, 2015PGE 40 (Alprostadil) 40 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1621-2015Class IITerminatedSep 23, 2015PGE 150Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1620-2015Class IITerminatedSep 23, 2015Oxytocin 100 units/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1619-2015Class IITerminatedSep 23, 2015Neomycin + Polymyxin B+ Bacitracin Ophthalmic OintmentLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1618-2015Class IITerminatedSep 23, 2015Nandrolone Decanoate 250 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1617-2015Class IITerminatedSep 23, 2015Nandrolone Decanoate 200 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1616-2015Class IITerminatedSep 23, 2015Morphine 70 mg/ml + Clonidine 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1615-2015Class IITerminatedSep 23, 2015Morphine 70 mg/ml + Bupivacaine 40 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1614-2015Class IITerminatedSep 23, 2015Morphine 64 mg/ml + Bupivacaine 10 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1613-2015Class IITerminatedSep 23, 2015Morphine 60 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1612-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml +Fentanyl 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1611-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Clonidine 200 mcg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1610-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Clonidine 100 mcg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1609-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Bupivacaine 2.5 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1608-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1607-2015Class IITerminatedSep 23, 2015Morphine 45 mg/ml + Bupivacaine 40 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1606-2015Class IITerminatedSep 23, 2015Morphine 45 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1605-2015Class IITerminatedSep 23, 2015Morphine 42 mg/ml + Bupivacaine 8 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1604-2015Class IITerminatedSep 23, 2015Morphine 40 mg/ml + Fentanyl 2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1603-2015Class IITerminatedSep 23, 2015Morphine 40 mg/ml + Clonidine 500 mcg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1602-2015Class IITerminatedSep 23, 2015Morphine 40 mg/ml + Bupivacaine 8 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1601-2015Class IITerminatedSep 23, 2015Morphine 40 mg/ml + Bupivacaine 16 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1600-2015Class IITerminatedSep 23, 2015Morphine 40 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1599-2015Class IITerminatedSep 23, 2015Morphine 36 mg/ml + Bupivacaine 40 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1598-2015Class IITerminatedSep 23, 2015Morphine 35 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1597-2015Class IITerminatedSep 23, 2015Morphine 33 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1596-2015